QUOTE AND NEWS
newratings.com  Sep 13  Comment 
WASHINGTON (dpa-AFX) - Ligand Pharmaceuticals Inc. (LGND) announced the initiation of a Phase 2 clinical trial with the company's glucagon receptor antagonist LGD-6972 for the treatment of type 2 diabetes mellitus. The randomized,...
FierceBiotech  Sep 7  Comment 
Retrophin, Ligand up on positive PhII data in rare kidney disorder slawrence Wed, 09/07/2016 - 10:32
newratings.com  Sep 7  Comment 
WASHINGTON (dpa-AFX) - Ligand Pharmaceuticals Inc. (LGND) partner Retrophin, Inc. (RTRX) reported positive top-line results from the Phase 2 DUET study of sparsentan for the treatment of focal segmental glomerulosclerosis, a kidney disorder...
Benzinga  Sep 7  Comment 
  Analysts at CIBC upgraded Spectra Energy Corp. (NYSE: SE) from Sector Performer to Outperformer. Spectra Energy shares declined 1.10 percent to $40.55 in pre-market trading. Deutsche Bank upgraded Ligand Pharmaceuticals Inc. ...
Benzinga  Aug 24  Comment 
Shares of Mylan NV (NASDAQ: MYL) have tumbled 10 percent this week over concerns regarding its huge price increase for its Epipen product. The entire biotech sector crashed Wednesday, after Democratic Presidential nominee Hillary Clinton...
Benzinga  Aug 24  Comment 
$108.97 - Intraday high $108.07 - Tuesday close $106.00 - Area of last three lows $102.95 - Current price as of 3:25 PM $101.69 - Intraday low as of 3:25 PM $101.15 - March 29 low $100.81 - March 28 low $98.61 -...
Benzinga  Aug 17  Comment 
Ligand Pharmaceuticals Inc. (NASDAQ: LGND) hit a 52-week high of $139.79 at the beginning of August. Since then, the stock has been steadily declining and as of Wednesday was trading for less than $109 per share. The stock is now nearly flat...
Benzinga  Aug 17  Comment 
$139.79 - August 1 high (all-time-high) $138.53 - August 1 close (all-time-closing high) $113.47 - Monday close $113.25 - Tuesday high $111.31 - Intraday high as of 12:16 PM $110.92 - Tuesday close $110.42 -...
Benzinga  Aug 11  Comment 
Shares of Ligand Pharmaceuticals Inc. (NASDAQ: LGND) have gained 6.1 percent over the year, posting a performance similar to that of the Dow Jones Industrial Average. Over the past six months, however, the stock moved up more than 30 percent. The...





You may also be interested in articles related to Ligand Pharmaceuticals (LGND):
 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki